Citizen Petition from American College of Obstetricians and Gynecologists

The commenter argues that the petition is spurious and that the FDA's reported adverse event rates for mifepristone are significantly lower than independent estimates. They advocate for greater controls on the medication based on these safety concerns.

Stephen Ghostley opposes the FDA's proposal to weaken safety protocols and remove Risk Evaluation and Mitigation Strategy (REMs) requirements for mifepristone. He argues that the drug poses significant risks to women's health and should be subject to strict regulation based on reported adverse events and deaths.

Michael Reilly opposes the FDA's proposal to weaken safety protocols and remove Risk Evaluation and Mitigation Strategy (REMs) requirements for mifepristone. He argues that the drug poses significant risks to women's health and should be subject to strict regulation based on reported adverse events and deaths.

Br. Mark Gehret opposes the FDA's proposal to weaken safety protocols and remove Risk Evaluation and Mitigation Strategy (REMs) requirements for mifepristone. He argues that the drug poses significant risks to women's health and should be subject to strict regulation and robust safety measures.

A registered nurse (RN) is expressing outrage over the lack of a reporting mechanism for adverse reactions to abortion medications. The commenter supports the petition by arguing that the FDA should be held accountable for the safety of these drugs and that medical personnel need a way to report dangerous outcomes.

A board-certified OB/GYN and member of ACOG opposes the citizen petition. The commenter argues that the current unsupervised use of mifepristone is a political rather than scientific decision and urges the FDA to reinstate pre-2016 REMS requirements.